In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Omeros (OMER – Research Report), with a price target of $34.00. The company’s shares closed last Monday at $14.80.
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.6% and a 43.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.
Currently, the analyst consensus on Omeros is a Moderate Buy with an average price target of $25.67.
The company has a one-year high of $20.92 and a one-year low of $10.30. Currently, Omeros has an average volume of 397K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.